Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones

por Haas W, Sanfilippo CM, Hesje CK, Morris TW
Publicado 2013

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections

por Silverstein BE, Morris TW, Gearinger LS, DeCory HH, Comstock TL
Publicado 2012

Acanthamoeba encystment: multifactorial effects of buffers, biocides, and demulcents present in contact lens care solutions

por Kovacs CJ, Lynch SC, Rah MJ, Millard KA, Morris TW
Publicado 2015

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility prof...

por Haas W, Gearinger LS, Usner DW, DeCory HH, Morris TW
Publicado 2011

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes

por Morris TW, Gearinger LS, Usner DW, Paterno MR, DeCory HH, Comstock TL, Haas W
Publicado 2011

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery

por Bucci FA Jr, Evans RE, Amico LM, Morris TW, Fluet AT, Sanfilippo CM, DeCory HH, Comstock TL
Publicado 2015